InventisBio has announced promising Phase III trial results for nomelcitinib in treating moderate to severe plaque psoriasis, showcasing significant efficacy and safety.

KRAS Inhibitors Drugs Market KRAS Inhibitors companies working in the market are Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others (Albany, USA) In 2024, the United States held nearly 70% of the KRAS inhibitors market across the 7MM, driven by a high burden of KRAS-mutated cancers, especially NSCLC, which accounts for 46% of such cases in the region.

New WRN inhibitors disclosed in Inventisbio patent  BioWorld MedTech

InventisBio recently announced positive results for D-2570 in a Phase 2 study. This oral TYK2 inhibitor shows significant promise in treating severe psoriasis effectively.

– D-2570 demonstrates robust efficacy and favorable safety profile, achieving skin clearance comparable to leading biologics – SHANGHAI, Dec. 3, 2024 /PRNewswire/ -- InventisBio Co., Ltd. today announced promising results from a Phase 2 clinical trial of…

Plus, news about IPOs in Hong Kong, InventisBio and Alligator Bioscience: Bristol Myers Squibb partners with AI Proteins: The deal will focus on designing what the companies describe as “miniproteins” and ...